Among patients with gout, treatment with at least 300 mg allopurinol daily was associated with a 13% reduced risk for kidney function decline, according to data published in JAMA Internal Medicine.

Arhalofenate (800mg) is safe and significantly decreases gout flares compared to allopurinol (300mg), according to a study published online July 27 in Arthritis & Rheumatology. HealthDay News — ...

The effects of allopurinol treatment on mortality among patients with gout remain uncertain, with a new meta-analysis finding conflicting results. In a systematic review of the literature that ...

Allopurinol didn't provide renal protection, according to the results of two randomized trials. Researchers have long debated whether hyperuricemia causes decline in renal function. In two randomized ...

December 16, 2011 — A retrospective analysis of data from 222 hyperuricemic women with gout who had participated in phase 3 comparative trials showed that febuxostat, 80 mg/d, was more effective than ...

Philadelphia, October 17, 2009 – Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric ...

RESEARCH TRIANGLE PARK, N.C., Oct 05, 2011 (BUSINESS WIRE) -- BioCryst Pharmaceuticals, Inc. BCRX +9.54% today announced positive top-line results from its Phase 2b randomized, double-blind, ...

Please provide your email address to receive an email when new articles are posted on . Rasburicase reduced and normalized plasma uric acid more quickly and effectively than allopurinol in adult ...

Indoco Remedies Ltd has informed BSE that the Company has received the approval from United States Food & Drug Administration (USFDA) to manufacture and market Allopurinol 100 mg & 300 mg ...

Patients had failed to reach the clinically important serum uric acid (sUA) goal of <6 mg/dL on allopurinol alone. Detailed study findings will be shared at an upcoming medical meeting. The study ...

Chicago, IL - Results of a phase 3, randomized, double-blind study show that febuxostat (TAP Pharmaceutical Products) is more effective in lowering serum uric acid than the current standard of care, ...

The Lupin stock was trading higher by 2.93 per cent, or Rs 36.50, at Rs 1282.15 at 9:38 am on Monday. The company's market cap at the time of writing this news stood at Rs 58,322.45 crore. "Global ...